2020
|
|

Abstract: Rituximab‐containing regimens are commonly used for frontline therapy in patients with symptomatic Waldenström macroglobulinemia (WM). We had observed that a portion of WM patients experienced deepening of response months to years after therapy completion. We carried a retrospective study aimed at describing this phenomenon. We gathered baseline data, and responses at end of induction, end of maintenance and best response. Deepening of response was defined as ≥25% decrease in serum IgM achieved at a later time… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
0
2
0

Publication Types

Select...

Relationship

0
0

Authors

Journals